



Cannabis Use During Pregnancy: Exploring Mental Health Implications and Intervention Gaps

Jeren Ghoujegli, MS2

Shontreal Cooper, MD

Introduction

- Cannabis is the most widely used drug during pregnancy³ (self-reported use is 5% and up to 28% in socioeconomically disadvantaged groups)², with usage being highest in the first trimester.¹
 - As cannabis is federally illegal, there is limited and unclear research regarding its effects during pregnancy.¹¹
- Due to stigma and a lack of information from providers, pregnant individuals rely on peers and online sources for information and recommendations.^{6,7}
 - In a study of 400 Colorado dispensaries, 69% recommended cannabis to treat morning sickness in the first trimester.⁵
- The American College of Obstetrician-Gynecologists (ACOG) recommends universal screening through validated tools and interviews, rather than drugs screening.¹
 - Reports of positive drug tests disproportionately affect Black and minority women.
 - Focus on risk-reducing strategies, rather than penalizing patients.
- Focus question: In what ways does maternal mental health influence perinatal cannabis use, and what gaps in clinical interventions exist to address this issue?

Methods

- Conducted a literature review of 11 articles from PubMed and 2 articles from ACOG.
- Inclusion criteria: articles published in the last 10 years addressing cannabis use in pregnant people, and its relation to mental health and/or provider interventions.
 - 12/13 articles were published in the last 5 years.
- Focused on reasons for self-medication, maternal mental health, and provider challenges.

Results

- Common reasons for perinatal cannabis usage included symptom relief, anxiety/stress, and believing it is more effective and safe than prescription medicine.⁷
 - Cannabis withdrawal syndrome can mimic pregnancy symptoms, such as morning sickness.³
- All major classes of mental health disorders were significantly linked to past-year cannabis use in pregnant people.⁴
 - **Anxiety disorders: aOR = 1.90**¹³
 - **Depressive disorders: aOR = 2.25**¹³
 - Incidence of cannabis use disorder was 5.3% or 19% of all pregnant cannabis users (n=227).⁹
- There are 3 decision frameworks that motivate limiting or abstaining for perinatal cannabis usage.⁶




Figure 1: Decision Types for Perinatal Cannabis Usage

Intervention Gaps

- Increased screening is needed throughout pregnancy and the first postpartum year.⁴
 - Interventions require a multidisciplinary approach.³
- Clinicians' uncertainty about cannabis safety and counselling strategies is a barrier to effective care.
 - When patients disclosed marijuana use, obstetric providers responded in about half of the encounters, primarily addressing legal and procedural issues rather than discussing health or medical consequences.^{6,10}

Conclusions

- Public health messaging and clinician awareness are needed to counter misinformation from online sources and dispensaries.
- Greater education and training is needed for providers to adopt strategies that focus on harm reduction, trauma-informed care, and motivational interviewing.
 - Emphasize reducing stigma, understanding patient's social context, and helping patients create individualized goals that support withdrawal and promote alternative treatment options.
 - Identify trauma history, mental health history, and substance use history in early pregnancy.
- Further research is needed to examine how providers can effectively engage and counsel patients on perinatal cannabis usage as well as alternative treatment options for symptom relief.

References

1. The American College of Obstetricians and Gynecologists. ACOG Releases New Recommendations on Cannabis Use in Pregnancy and Lactation. Accessed October 20, 2025. <https://www.acog.org/news/news-releases/2025/09/acog-releases-new-recommendations-cannabis-use-pregnancy-lactation>
2. The American College of Obstetricians and Gynecologists. Marijuana use during pregnancy and lactation. Accessed April 4, 2024. <https://www.acog.org/clinical/clinical-guidance/commit-tee-opinion/articles/2017/10/marijuana-use-during-pregnancy-and-lactation>
3. Bayrampour H, Asim A. Cannabis Use During the Pre-Conception Period and Pregnancy After Legalization. J Obstet Gynaecol Can. 2021 Jun;43(6):740-745. doi: 10.1016/j.jogc.2021.02.119. Epub 2021 Mar 5. PMID: 33677139.
4. Brown QL, Shmulewitz D, Sarvet AL, Young-Wolff KC, Howard T, Hasin DS. Cannabis use, cannabis use disorder and mental health disorders among pregnant and postpartum women in the US: A nationally representative study. Drug Alcohol Depend. 2023;248:109940. doi:10.1016/j.drugalcdep.2023.109940
5. Dickson B, Mansfield C, Guaihi M, et al. Recommendations From Cannabis Dispensaries About First-Trimester Cannabis Use. Obstet Gynecol. 2018;131(6):1031-1038. doi:10.1097/AOG.0000000000002619
6. Greyson D, Roosevelt L, Boyd CJ. Desistance, Self-treatment, or Substitution: Decisions about Cannabis Use During Pregnancy. J Midwifery Womens Health. 2021;66(1):96-100. doi:10.1111/jmwh.13205
7. Gunn RL, Aston ER, Artis L, Nesi J, Pedersen ER, Micalizzi L. Use of cannabis to manage symptoms of mental and physical health conditions during pregnancy: analysis of a pro-cannabis pregnancy forum. Front Psychiatry. 2024;15:1478505. Published 2024 Dec 10. doi:10.3389/fpsy.2024.1478505
8. Jones A, Blair LM, Kurzer JA, et al. Identifying adverse childhood experiences and mental health needs among a small sample of pregnant women who use cannabis. Front Psychiatry. 2025;16:1616463. Published 2025 Aug 25. doi:10.3389/fpsy.2025.1616463
9. Leng QL, Lo JO, Rakshe S, et al. The association between preconception cannabis use and depression and anxiety during pregnancy. Gen Hosp Psychiatry. 2023;83:148-155. doi:10.1016/j.genhosppsych.2023.05.006
10. Panday J, Taneja S, Popoola A, et al. Clinician responses to cannabis use during pregnancy and lactation: a systematic review and integrative mixed-methods research synthesis. Fam Pract. 2022;39(3):504-514. doi:10.1093/fampra/cmab146
11. Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miala A, Croatto G, Baggio F, Michelson S, Ballan L, Gerde B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbuti C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023 Aug 30;382:e072348. doi: 10.1136/bmj-2022-072348. PMID: 37648266; PMCID: PMC10466434.
12. Towobola A, Towobola B, Nair B, Makwana A. The ethics and management of cannabis use in pregnancy following decriminalisation and licensing for medical use: narrative review. BJPsych Bull. 2023;47(1):28-37. doi:10.1192/bjb.2021.102
13. Young-Wolff KC, Chi FW, Campbell CI, Does MB, Brown QL, Alexeeff SE, Ansley D, Wang X, Lapham GT. Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California. Addiction. 2024 Nov;119(11):1987-1997. doi: 10.1111/add.16622. Epub 2024 Jul 31. PMID: 39082097; PMCID: PMC12091947.